Disease-specific haptoglobin-? chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases.

ABSTRACT: Background: The association of pathological states with N-glycosylation of haptoglobin-? has attracted increasing attention. Materials & Methods: In the present study, disease-specific haptoglobin-? (DSHp-?) was separated from serum immunoinflammation-related protein complexes (IIRPCs) of 600 participants including 300 patients with benign lung diseases (BLDs) and 300 patients with non-small cell lung cancer (NSCLC). The enriched glycopeptides of the tryptic digests of the DSHp-? were analyzed using matrix assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS). Results: 20 of glycopeptides were detected for each sample. The statistical analysis has indicated that significant changes in the sialylation of DSHp-? between BLDs and NSCLC patients were observed. The age- and sex-matched participants were randomly clarified into the training set and the validation set. Receiver operating characteristic (ROC) analysis has revealed that the level ratio of glycopeptides (G2G3/G2G3S4) at the sites of Asn207/211 has potential capability to distinguish BLDs from NSCLC, with the sensitivity of 74.4%, the specificity of 82.8%, and the area under curve (AUC) of 0.805. Conclusion: The glycosylation of DSHp-? can distinguish NSCLC from BLDs with high diagnostic accuracy compared with current clinical available serum markers.

SUBMITTER: Chen T 

PROVIDER: S-EPMC6843889 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature